These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 36759495)
1. Tertiary Lymphoid Structures Are Associated with a Favorable Prognosis in High-Grade Serous Ovarian Cancer Patients. Zhang K; Xie X; Zou LH; Guo SQ Reprod Sci; 2023 Aug; 30(8):2468-2480. PubMed ID: 36759495 [TBL] [Abstract][Full Text] [Related]
2. Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer. An Y; Sun JX; Xu MY; Xu JZ; Ma SY; Liu CQ; Liu Z; Wang SG; Xia QD Front Immunol; 2022; 13():1049884. PubMed ID: 36420257 [TBL] [Abstract][Full Text] [Related]
3. The impact of tertiary lymphoid structures on tumor prognosis and the immune microenvironment in non-small cell lung cancer. Weng Y; Yuan J; Cui X; Wang J; Chen H; Xu L; Chen X; Peng M; Song Q Sci Rep; 2024 Jul; 14(1):16246. PubMed ID: 39009684 [TBL] [Abstract][Full Text] [Related]
4. The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer. Wang B; Liu J; Han Y; Deng Y; Li J; Jiang Y Front Immunol; 2022; 13():868155. PubMed ID: 35664009 [TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of tertiary lymphoid structures and immune infiltration in ccRCC microenvironment revealed their clinical significances: a multicenter cohort study. Wang YQ; Chen WJ; Zhou W; Dong KQ; Zuo L; Xu D; Chen JX; Chen WJ; Li WY; Liu ZC; Jiang ZY; Tang YF; Qin YX; Wang LH; Pan XW; Cui XG J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908856 [TBL] [Abstract][Full Text] [Related]
6. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. Calderaro J; Petitprez F; Becht E; Laurent A; Hirsch TZ; Rousseau B; Luciani A; Amaddeo G; Derman J; Charpy C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C J Hepatol; 2019 Jan; 70(1):58-65. PubMed ID: 30213589 [TBL] [Abstract][Full Text] [Related]
7. Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma. Liang H; Zhang Z; Guan Z; Zheng S; Lou J; Liu W; Cai Q; Si Y Front Immunol; 2023; 14():1096220. PubMed ID: 36776859 [TBL] [Abstract][Full Text] [Related]
8. HLA-A Zhang D; Jiang D; Jiang L; Ma J; Wang X; Xu X; Chen Z; Jiang M; Ye W; Wang J; Meng W; Qiu W; Hou Y; Huang J; Jiao Y; Liu Y; Liu Z Br J Cancer; 2024 Jul; 131(1):184-195. PubMed ID: 38762674 [TBL] [Abstract][Full Text] [Related]
9. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment. Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023 [TBL] [Abstract][Full Text] [Related]
10. Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma. Liu Z; Meng X; Tang X; Zou W; He Y Cancer Immunol Immunother; 2023 Jun; 72(6):1505-1521. PubMed ID: 36481914 [TBL] [Abstract][Full Text] [Related]
11. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206 [TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma. Deguchi S; Tanaka H; Suzuki S; Natsuki S; Mori T; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M BMC Cancer; 2022 Jun; 22(1):699. PubMed ID: 35751038 [TBL] [Abstract][Full Text] [Related]
13. A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy. Li X; Wan Z; Liu X; Ou K; Yang L Med Oncol; 2022 Jan; 39(4):43. PubMed ID: 35092511 [TBL] [Abstract][Full Text] [Related]
14. Deciphering the immune landscape dominated by cancer-associated fibroblasts to investigate their potential in indicating prognosis and guiding therapeutic regimens in high grade serous ovarian carcinoma. Li Y; Tian R; Liu J; Li J; Tan H; Wu Q; Fu X Front Immunol; 2022; 13():940801. PubMed ID: 36119108 [TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of tertiary lymphoid structures and immune microenvironment in patients with esophageal carcinoma. Yao Y; Xuan H; Wang J; Gong L; Gao W Tumori; 2023 Oct; 109(5):466-480. PubMed ID: 37249074 [TBL] [Abstract][Full Text] [Related]
16. Integrating tertiary lymphoid structure-associated genes into computational models to evaluate prognostication and immune infiltration in pancreatic cancer. Ma Y; Li X; Zhang J; Zhao X; Lu Y; Shen G; Wang G; Liu H; Hao J J Leukoc Biol; 2024 Sep; 116(3):589-600. PubMed ID: 38484172 [TBL] [Abstract][Full Text] [Related]
17. The distribution and maturation of tertiary lymphoid structures can predict clinical outcomes of patients with gastric adenocarcinoma. Sun H; Liu Y; Cheng W; Xiong R; Gu W; Zhang X; Wang X; Wang X; Tan C; Weng W; Zhang M; Ni S; Huang D; Xu M; Sheng W; Wang L Front Immunol; 2024; 15():1396808. PubMed ID: 39136032 [TBL] [Abstract][Full Text] [Related]
18. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies. Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X Front Immunol; 2023; 14():1164408. PubMed ID: 37090728 [TBL] [Abstract][Full Text] [Related]
19. Peritumoral tertiary lymphoid structure and tumor stroma percentage predict the prognosis of patients with non-metastatic colorectal cancer. Wang Q; Shen X; An R; Bai J; Dong J; Cai H; Zhu H; Zhong W; Chen W; Liu A; Du J Front Immunol; 2022; 13():962056. PubMed ID: 36189233 [TBL] [Abstract][Full Text] [Related]
20. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. Ding GY; Ma JQ; Yun JP; Chen X; Ling Y; Zhang S; Shi JY; Chang YQ; Ji Y; Wang XY; Tan WM; Yuan KF; Yan B; Zhang XM; Liang F; Zhou J; Fan J; Zeng Y; Cai MY; Gao Q J Hepatol; 2022 Mar; 76(3):608-618. PubMed ID: 34793865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]